Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Pierdomenico

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Leukemia Research Reports|December 28, 2013
Treatment of acute erythroleukemia with Azacitidine: A case seriesFrancesca Pierdomenico, Antonio Almeida
Hematology Reports|June 25, 2025
Multi-Organ Adverse Reaction to Two Hypomethylating Agents: A Challenge in High-Risk Myelodysplastic Syndrome TreatmentSofia Brites Alves, Francesca Pierdomenico
Annals of Hematology|April 23, 2013
Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDSFrancesca Pierdomenico, Susana Esteves, Antonio Almeida
Case Reports in Oncological Medicine|June 14, 2013
Burkitt's Lymphoma in a Pregnant Woman: Case Report and Review of the LiteratureCarlos Zagalo, Francesca Pierdomenico, José Cabeçadas, et al.
Dermatology and Therapy|March 28, 2016
Schnitzler Syndrome: A Dramatic Response to AnakinraAna Isabel Gouveia, Manuela Micaelo, Francesca Pierdomenico, et al.
Leukemia Research|May 22, 2012
Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature reviewMichael Thorpe, Ana Montalvão, Francesca Pierdomenico, et al.
Hematology Reports|March 28, 2023
Extramedullary T-lymphoblastic Crisis in a Myelodysplastic/Myeloproliferative Neoplasm with a t(12;22)/<i>MN1::ETV6</i> TranslocationAna Carolina Freitas, Tiago Maia, Joana Desterro, et al.
Acta Medica Portuguesa|August 26, 2019
Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical PracticeAntonio Almeida, Francesca Pierdomenico, Blanca Polo Guerrero, et al.
Leukemia Research Reports|January 10, 2017
Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter studyAntónio Almeida, Ana Rita Ferreira, Maria João Costa, et al.
Journal of Hematology & Oncology|August 29, 2021
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialFarhad Ravandi, Gail J Roboz, Andrew H Wei, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Leukemia Research Reports|December 28, 2013
Treatment of acute erythroleukemia with Azacitidine: A case seriesFrancesca Pierdomenico, Antonio Almeida
Hematology Reports|June 25, 2025
Multi-Organ Adverse Reaction to Two Hypomethylating Agents: A Challenge in High-Risk Myelodysplastic Syndrome TreatmentSofia Brites Alves, Francesca Pierdomenico
Annals of Hematology|April 23, 2013
Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDSFrancesca Pierdomenico, Susana Esteves, Antonio Almeida
Case Reports in Oncological Medicine|June 14, 2013
Burkitt's Lymphoma in a Pregnant Woman: Case Report and Review of the LiteratureCarlos Zagalo, Francesca Pierdomenico, José Cabeçadas, et al.
Dermatology and Therapy|March 28, 2016
Schnitzler Syndrome: A Dramatic Response to AnakinraAna Isabel Gouveia, Manuela Micaelo, Francesca Pierdomenico, et al.
Leukemia Research|May 22, 2012
Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature reviewMichael Thorpe, Ana Montalvão, Francesca Pierdomenico, et al.
Hematology Reports|March 28, 2023
Extramedullary T-lymphoblastic Crisis in a Myelodysplastic/Myeloproliferative Neoplasm with a t(12;22)/<i>MN1::ETV6</i> TranslocationAna Carolina Freitas, Tiago Maia, Joana Desterro, et al.
Acta Medica Portuguesa|August 26, 2019
Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical PracticeAntonio Almeida, Francesca Pierdomenico, Blanca Polo Guerrero, et al.
Leukemia Research Reports|January 10, 2017
Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter studyAntónio Almeida, Ana Rita Ferreira, Maria João Costa, et al.
Journal of Hematology & Oncology|August 29, 2021
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialFarhad Ravandi, Gail J Roboz, Andrew H Wei, et al.
Pageof 1